Companies /Healthcare
Biomarin Pharmaceutical Inc
NASDAQ: BMRN Biotechnology
$60.57
▲ $2.06 (+3.52%) today
Markets open · 12:39pm ET

BioMarin (BMRN) Q3 2026 Earnings

Reported Nov 2, 2026, 4:03pm ET
$0.23
Beat +304.81%
EPS · est. $-0.11 Adjusted

Non-GAAP EPS includes acquired IPR&D charges of $287.7 million (287,685 thousand) recorded in the quarter in connection with the Alesta Therapeutics acquisition; company expects Alesta and BMN 450 charges of approximately $320 million and $83 million for full-year 2026 (approximately $1.55 and $0.32 per share). GAAP diluted EPS of $(0.63) also reflects Amicus-related intangible amortization ($99 million), inventory step-up amortization ($18 million) and acquisition/restructuring costs ($47 million).

$1.0B
Beat +0.22%
Revenue · est. $1.0B
2 quarters
Consecutive EPS beats

How Did BMRN Stock React to Q3 2026 Earnings?

% change · around the report
0+3%+6%+9%Nov 2Nov 3report 4:03pm ETearnings+0.2%+3.9%
0+3%+6%+9%Nov 2Nov 3earnings+0.2%+3.9%
BMRN +3.9%S&P 500 +0.2%
0+3%+6%+9%Nov 2Nov 3report 4:03pm ETearnings+0.4%+3.9%
0+3%+6%+9%Nov 2Nov 3earnings+0.4%+3.9%
BMRN +3.9%NASDAQ +0.4%
−3.10%
Day of report
+2.64%
Next session
+2.64%
One week

Did BMRN Beat Earnings? Q3 2026 Results

Yes. BioMarin reported Q3 2026 earnings of $0.23 a share on Nov 2, 2026, beating the $-0.11 consensus estimate by 304.8%. Revenue was $1.0B against a $1.0B estimate.

BioMarin Pharmaceutical delivered a decisive earnings beat in Q3 2026, its first full quarter absorbing the Amicus Therapeutics product portfolio, as adjusted non-GAAP EPS of $0.23 cleared the consensus estimate of negative $0.11 by 304.81% while revenue of $1.02 billion edged ahead of expectations and climbed 32.0% year over year. The Amicus integration was the clear engine of that growth, with GALAFOLD contributing $152.00 million and POMBILITI + OPFOLDA adding $49.00 million as patient counts rose sharply across both therapies. The GAAP picture was far cloudier: a $287.69 million acquired in-process R&D charge tied to the Alesta Therapeutics acquisition, alongside $99.46 million of intangible amortization and $55.63 million of interest expense on acquisition debt, pushed the GAAP net loss to $123.00 million. Looking ahead, BioMarin trimmed its full-year 2026 revenue outlook to $3.80 billion to $3.90 billion, partly on uncertain order timing from a single international customer, and lowered its non-GAAP diluted EPS guidance to $2.80 to $3.10, reflecting roughly $403.00 million in combined Alesta and BMN 450 pre-tax charges.

Key Takeaways
  • Addition of GALAFOLD ($152M) and POMBILITI + OPFOLDA ($49M) from the Amicus acquisition
  • Patients treated with GALAFOLD and POMBILITI + OPFOLDA up about 13% and 69% Y/Y
  • POMBILITI + OPFOLDA uptake helped by supply constraints for other Pompe therapies
  • VIMIZIM revenue up 18% on timing of large international orders
  • VOXZOGO up 12%, with children treated up 17% Y/Y across 58 countries
  • NAGLAZYME down 11% on timing of large international orders
  • GAAP loss widened on Amicus intangible amortization, interest expense, inventory step-up and integration costs, plus the Alesta IPR&D charge
  • Higher sales and marketing spend for GALAFOLD and POMBILITI + OPFOLDA

“BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world. For the first time, quarterly revenue exceeded $1 billion, a milestone for BioMarin.”

BioMarin CEO, on the earnings call

What Is BioMarin's Outlook?

BioMarin updated its full-year 2026 guidance to reflect order-timing uncertainty and two acquired IPR&D charges. - Total revenues: $3,800–$3,900 million, from $3,875–$3,925 million; implies 20% midpoint growth. - Metabolic Conditions: $2,675–$2,750 million; 29% midpoint growth. - VOXZOGO: $975–$1,025 million; 8% midpoint growth. - Other revenues: $125–$150 million, from $100–$125 million. - Non-GAAP diluted EPS: $2.80–$3.10, from $4.90–$5.10; based on about 200 million diluted shares. The EPS cut reflects about $320 million (Alesta) and $83 million (BMN 450) of pre-tax charges, or roughly $1.55 and $0.32 per share. A large international VOXZOGO order has moved from Q3 to Q4. Upcoming milestones: - VOXZOGO achondroplasia full-approval PDUFA date: February 28, 2027. - VOXZOGO hypochondroplasia PDUFA date: May 30, 2027. - BMN 333 and BMN 440 data: 2027. - BMN 820 pivotal data: 2028. - Amicus cost synergies of about $280 million GAAP (about $220 million non-GAAP) fully realized in 2028.

BMRN YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$400.0M$800.0M$776.1M$1.0BRevenue$-339,037,588$-82,081,000Operating Income
$0$400.0M$800.0MRevenueOperating Income
BMRN income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $1.0B $776.1M +32.0%
Operating Income −$82.1M −$339.0M −75.8%

BMRN Revenue by Segment

VOXZOGO$245.0M+12.0%
VIMIZIM$216.0M+18.0%
GALAFOLD$152.0M
NAGLAZYME$108.0M−11.0%
PALYNZIQ$111.0M+2.0%
ALDURAZYME$57.0M+6.0%
BRINEURA$53.0M+10.0%
POMBILITI + OPFOLDA$49.0M

Figures from SEC filings and company reports. Not investment advice.